Design and evaluation of albumin nanoparticles for the delivery of a novel β-tubulin polymerization inhibitor

Design and evaluation of albumin nanoparticles for the delivery of a novel β-tubulin polymerization inhibitor

The ultimate goal of this study is to develop a novel delivery system for a new potent cytotoxic compound, CCI-001, with anti-b tubulin activity, so that the drug can be effectively administered and at the same time its harmful side effects can be reduced. In the current study, CCI-001 was loaded in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacy & pharmaceutical sciences Vol. 24; no. 3; pp. 344 - 362
Main Authors: Spada, Alessandra, Emami, Jaber, Sanaee, Foroughalsadat, Aminpour, Maral, Paiva, Igor M, Tuszynski, Jack, Lavasanifar, Afsaneh
Format: Journal Article
Language:English
Published: Canada Frontiers Media S.A 2021
Subjects:
Animals
Cattle
Cell Line, Tumor
Chemistry, Pharmaceutical
Colorectal Neoplasms - drug therapy
Drug Carriers - chemistry
Drug Delivery Systems
Drug Liberation
HCT116 Cells
Humans
Nanoparticles
Particle Size
Serum Albumin, Bovine - chemistry
Serum Albumin, Human - chemistry
Tubulin Modulators - administration & dosage
Tubulin Modulators - chemistry
Tubulin Modulators - pharmacology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The ultimate goal of this study is to develop a novel delivery system for a new potent cytotoxic compound, CCI-001, with anti-b tubulin activity, so that the drug can be effectively administered and at the same time its harmful side effects can be reduced. In the current study, CCI-001 was loaded into serum albumin (SA), using a modified desolvation method, generating CCI-001-SA nanoparticles. Both bovine and human SA were used for the encapsulation of this drug candidate. Optimum conditions for drug loading were achieved when already formed and crosslinked albumin nanoparticles were incubated overnight at 37°C with CCI-001 solutions. The CCI-001-loaded albumin nanoparticles were assessed for average particle diameter and polydispersity, zeta potential, drug loading, in vitro release, morphology and cell toxicity against SW620 and HCT116 colorectal cancer cells. The spherical nanoparticles obtained were negatively charged (~ -30 mV) and had an average diameter of ~ 130 nm, with a narrow size distribution. The in vitro release of CCI-001 from the albumin nanoparticles showed a sustained release pattern over 24 hours without any initial burst release, compared to the fast release of the free drug under experimental conditions. No difference between the SA from the two species in terms of CCI-001 loading was observed. However, a significant difference was observed between the release profiles of CCI-001 from drug-loaded HSA and drug-loaded BSA nanoparticles with HSA nanoparticles showing slower drug release (mean release time, MRT, values of 5.14 ± 0.33 h and 6.88 ± 0.15 h for BSA-NPs and HSA-NPs, respectively, P < 0.01). Cellular toxicity studies showed higher cytotoxicity for CCI-001-SA compared to the free drug (IC50s of 0.62 ± 0.31 nM vs 2.06 ± 0.29 nM in SW620 cells and 0.9 ± 0.1 nM vs 4.2 ± 0.2 nM in HCT116 cells, for CCI-001-HSA NPs and free drug, respectively). Therefore, despite the low drug content level in the HSA nanoparticles of CCI-001, the formulation provides relevant concentrations for further in vivo studies in animal models due to high drug potency. The data support the potential use of albumin as a nanocarrier for CCI-001 in biological systems.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1482-1826
1482-1826
DOI:10.18433/jpps31877